Buddlejasaponin IV

Buddlejasaponin IV (BS‐IV) exerts anti-inflammatory and cytotoxic effects against cancer cells[1].

Product Specifications

CAS Number

[139523-30-1]

UNSPSC

12352005

Target

COX; NO Synthase

Type

Natural Products

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/buddlejasaponin-iv.html

Solubility

10 mM in DMSO

Smiles

C[C@]12[C@]3(C=C[C@@]4([H])[C@]2(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](O)[C@@H](C)O6)O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)CO)O[C@]8([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]8O)CO)[C@@]5(C)CO)C)C)[C@@]9([H])[C@](CO3)(CCC(C)(C)C9)[C@@H](O)C1

Molecular Formula

C48H78O18

Molecular Weight

943.12

References & Citations

[1]Young Sun Hwang, et al. Buddlejasaponin IV induces cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes. Phytother Res. 2011 Oct;25 (10) :1503-10.|[2]Jong-Heon Won, et al. Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol. 2006 May;148 (2) :216-25.